Martin Jönsson | BiotechTV

top of page

Swiss Nordic Bio 2026: AlzeCure Pharma develops treatments for numerous CNS conditions - a recent Alzheimer's deal with Lilly made the headlines

CEO Martin Jönsson discusses AlzeCure's programs, including the gamma-secretase modulator that was out-licensed to Lilly, another recent deal with QuantumCell, and others. Coverage brought to you by

Company News

2 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page

Swiss Nordic Bio 2026: AlzeCure Pharma develops treatments for numerous CNS conditions - a recent Alzheimer's deal with Lilly made the headlines

Follow BiotechTV

Sponsors

Sponsor Spotlight